Targeting PKC-theta protein: a way to inhibit harmful immune responses?

November 09, 2009

For some individuals with leukemia, the best treatment option is to receive a bone marrow transplant from a person who is not an identical genetic match. The donor bone marrow gives rise to immune cells that attack the leukemia (a response known as a graft-versus leukemia [GVL] response). In some cases, however, the immune cells generated by the donor bone marrow attack other cells in the patient's body and this highly toxic response is known as graft-versus-host disease (GVHD). Much research is being conducted to identify drugs that can prevent GVHD but preserve GVL responses and responses against infectious agents. A team of researchers, led by Amer Beg and Xue-Zhong Yu, at the H. Lee Moffitt Cancer Center and Research Institute, Tampa, has now identified the protein PKC-theta as a potential drug target in this context by determining that it is required in mice for GVHD induction but not for GVL or protective responses to infectious agents.
-end-
TITLE: PKC-theta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice

AUTHOR CONTACT:

Amer A. Beg
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Phone: (813) 745-5714; Fax: (813) 979-7265; E-mail: amer.beg@moffitt.org.

Xue-Zhong Yu
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
Phone: (813) 745-3562; Fax: (813) 979-7265; E-mail: xue.yu@moffitt.org.

View this article at: http://www.jci.org/articles/view/39692?key=zd7vNZFNtFlFYjT9Mfn6

JCI Journals

Related Leukemia Articles from Brightsurf:

New therapeutic approach against leukemia
Using an RNA molecule complex, researchers can prevent retention of cancer stem cell in their tumor supporting niche

Nanoparticle for overcoming leukemia treatment resistance
One of the largest problems with cancer treatment is the development of resistance to anticancer therapies.

Key gene in leukemia discovered
Acute myeloid leukemia (AML) is one of the most common forms of blood cancer among adults and is associated with a low survival rate, and leads to the inhibition of normal blood formation.

Vitamin B6, leukemia's deadly addiction
Researchers from CSHL and Memorial Sloan Kettering Cancer Center have discovered how Acute Myeloid Leukemia is addicted to vitamin B6.

Artificial intelligence tracks down leukemia
Artificial intelligence can detect one of the most common forms of blood cancer - acute myeloid leukemia -- with high reliability.

Milestone reached in new leukemia drug
Using a chemical compound called YKL-05-099, a team of cancer researchers from CSHL and the Dana Farber Institute was able to target the Salt-Inducible Kinase 3 (SIK3) pathway and extend survival in mice with MLL leukemia.

The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.

Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.

Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.

An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.

Read More: Leukemia News and Leukemia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.